These findings have been instrumental in shaping criteria for diagnosis and treatment, so much that the presence of the JAK2 V617F mutation is a major criterion in the diagnosis of PV [1] and JAK2 inhibitors are in development as targeted molecular therapies for PV [3, 13]. The gene discussed is JAK2; the disease is acquired polycythemia vera.